Search Result
Results for "
cardiac channel
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
19
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P4898A
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
Anthopleurin-A TFA is a soidum channel toxin. Anthopleurin-A TFA is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A TFA can be isolated from the sea anemone .
|
-
-
- HY-W019726
-
|
BAY-b 4759
|
Drug Metabolite
|
Cardiovascular Disease
Cancer
|
|
Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies .
|
-
-
- HY-122605
-
|
CBA
|
TRP Channel
|
Cardiovascular Disease
Cancer
|
|
TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel TRPM4, with an IC50 of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer .
|
-
-
- HY-B0284
-
-
-
- HY-P1219
-
|
β-TRTX-Cj1α
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC50 of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype .
|
-
-
- HY-P4898
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
Anthopleurin-A is a soidum channel toxin. Anthopleurin-A is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A can be isolated from the sea anemone .
|
-
-
- HY-W019726R
-
|
|
Drug Metabolite
|
Cardiovascular Disease
Cancer
|
|
Dehydro Nifedipine (Standard) is the analytical standard of Dehydro Nifedipine. This product is intended for research and analytical applications. Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies .
|
-
-
- HY-P5772
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-II, a 32 amino acid residues including two acidic and two basic residues, is a neurotoxin. Jingzhaotoxin-II inhibits voltage-gated sodium channels (VGSC) that significantly slows rapid inactivation of TTX-resistant (TTX-R) VGSC on cardiac myocytes with the IC50 of 0.26 μM .
|
-
-
- HY-14924
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology .
|
-
-
- HY-167203
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
AJG049 free base is a calcium channel (Ca 2+ channel) antagonist. AJG049 free base regulates vascular relaxation, reduces cardiac load, and improves cardiac perfusion by binding to the binding site of L-type calcium channels, specifically Diltiazem (HY-B0632). AJG049 free base can be used in cardiovascular disease research .
|
-
-
- HY-12515A
-
-
-
- HY-105084A
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Lubeluzole (dihydrochloride) is a neuroprotective agent which blockades neuronal voltage-gated sodium channels. Lubeluzole (dihydrochloride) also produces both tonic and block of cardiac sodium channels. Lubeluzole (dihydrochloride) is promising for research of antiarrhythmic agents .
|
-
-
- HY-14834A
-
-
-
- HY-111018
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
FPL 62129 is an antagonist for calcium channel. FPL 62129 reduces blood pressure and total peripheral resistance, increases the cardiac contractility and cardiac output in anarsthetised beagle model. FPL 62129 also serves as a vasodilator and a direct decelerator .
|
-
-
- HY-12515
-
-
-
- HY-111747
-
|
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and <0.02 μg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization .
|
-
-
- HY-135356
-
|
|
Drug Metabolite
|
Cardiovascular Disease
|
|
m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies .
|
-
-
- HY-18940A
-
-
-
- HY-B0341
-
|
SG-75
|
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-120672
-
-
-
- HY-B0284S1
-
-
-
- HY-12515B
-
|
(S)-YC-93 free base
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
(S)-Nicardipine ((S)-YC-93 free base) is the less active S enantiomer of Nicardipine. Nicardipine is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-12515AS
-
|
YC-93-d3
|
Calcium Channel
|
Neurological Disease
|
|
Nicardipine-d3 hydrochloride (YC-93 D3) is the deuterium labeled Nicardipine hydrochloride. Nicardipine hydrochloride is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-12515AS2
-
|
YC-93-d4
|
Autophagy
Calcium Channel
Isotope-Labeled Compounds
|
Neurological Disease
Cancer
|
|
Nicardipine-d4 hydrochloride is deuterated labeled Nicardipine hydrochloride (HY-12515A). Nicardipine hydrochloride (YC-93) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-12515AR
-
|
YC-93 (Standard)
|
Reference Standards
Calcium Channel
Autophagy
|
Neurological Disease
Cancer
|
|
Nicardipine (hydrochloride) (Standard) is the analytical standard of Nicardipine (hydrochloride). This product is intended for research and analytical applications. Nicardipine hydrochloride (YC-93) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-169333
-
|
1,4-DHP
|
Calcium Channel
|
Cardiovascular Disease
|
|
1,4-Dihydropyridine is an inhibitor for calcium channel, that blocks the L-type calcium channels, reduces the influx of calcium ions into cardiac and vascular smooth muscle cells, and thus reduces the contractility and heart rate of the heart, dilates blood vessels, and lowers blood pressure .
|
-
-
- HY-B0284R
-
|
BAY-a-1040 (Standard)
|
Calcium Channel
Autophagy
|
Cardiovascular Disease
Cancer
|
|
Nifedipine (Standard) is the analytical standard of Nifedipine. This product is intended for research and analytical applications. Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
|
-
-
- HY-12533
-
|
Dicorantil; SC-7031
|
Sodium Channel
Potassium Channel
|
Cardiovascular Disease
|
|
Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
|
-
-
- HY-12533B
-
|
Dicorantil hydrochloride; SC-7031 hydrochloride
|
Sodium Channel
Potassium Channel
|
Cardiovascular Disease
|
|
Disopyramide hydrochloride is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide hydrochloride blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide hydrochloride inhibits HERG encoded potassium channels. Disopyramide hydrochloride also exhibits complex protein binding, and has a potent negative inotropic action .
|
-
-
- HY-12533A
-
|
Dicorantil phosphate; SC-7031 phosphate
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
|
-
-
- HY-B0341R
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil (Standard) is the analytical standard of Nicorandil. This product is intended for research and analytical applications. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-B0284S2
-
-
-
- HY-12515C
-
|
(R)-YC-93 free base
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
(R)-Nicardipine ((R)-YC-93 free base) is the less active R enantiomer of Nicardipine. Nicardipine (YC-93) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-12515R
-
|
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Nicardipine (Standard) is the analytical standard of Nicardipine. This product is intended for research and analytical applications. Nicardipine (YC-93 free base) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-18600
-
|
NE-10064
|
Potassium Channel
|
Cardiovascular Disease
|
|
Azimilide(NE-10064) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
|
-
-
- HY-18600A
-
|
NE-10064 dihydrochloride
|
Potassium Channel
|
Cardiovascular Disease
|
|
Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
|
-
-
- HY-B1440
-
|
|
Calcium Channel
Monoamine Oxidase
|
Cardiovascular Disease
|
|
Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease .
|
-
-
- HY-107754
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
Cesium chloride is a blocker of potassium channel. Cesium chloride prevents the decrease of Na + transport produced by Alloxan . Cesium chloride has induced cardiac arrhythmias, including torsade de pointes in animal models .
|
-
-
- HY-B0341S
-
|
|
Isotope-Labeled Compounds
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-B0632
-
|
|
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
Diltiazem is an orally active L-type Ca 2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .
|
-
-
- HY-116759
-
-
-
- HY-16952A
-
|
(±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate
|
Calcium Channel
|
Cardiovascular Disease
|
|
Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca + channel antagonist and Na +, K + channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac Na +/Ca2 + exchange (NCX1) inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders .
|
-
-
- HY-171782
-
|
|
Others
|
Cardiovascular Disease
|
|
Amidepin is a new type of antiarrhythmic compound. Amidepin has the activity of regulating cardiac electrical activity. The main regulatory mechanism of amidepin involves ion channel or receptor interaction. Amidepin can be used for the study of arrhythmias .
|
-
-
- HY-17429
-
|
R-818
|
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.
|
-
-
- HY-120774
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
GS-462808 is an oral active late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with the IC50 of 1.33 μM. GS-462808 can be used for study of arrhythmia .
|
-
-
- HY-135356R
-
|
|
Drug Metabolite
Reference Standards
|
Cardiovascular Disease
|
|
m-Nifedipine (Standard) is the analytical standard of m-Nifedipine. This product is intended for research and analytical applications. m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies .
|
-
-
- HY-B0632A
-
|
MK 793
|
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
Diltiazem malate is a potent and orally active L-type calcium channel inhibitor. Diltiazem malate shows antihypertensive and antiarrhythmic effects. Diltiazem malate can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .
|
-
-
- HY-12533R
-
|
Dicorantil (Standard); SC-7031 (Standard)
|
Reference Standards
Sodium Channel
Potassium Channel
|
Cardiovascular Disease
|
|
Disopyramide (Standard) is the analytical standard of Disopyramide. This product is intended for research and analytical applications. Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
|
-
-
- HY-12533AR
-
|
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Disopyramide (phosphate) (Standard) is the analytical standard of Disopyramide (phosphate). This product is intended for research and analytical applications. Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
|
-
-
- HY-120158
-
|
|
Potassium Channel
|
Neurological Disease
|
|
ZD0947 is an ATP-sensitive potassium channel activator with relatively effective activation of smooth muscle KATP channels (SUR2B/Kir6.1 and SUR2B/Kir6.2). ZD0947 partially antagonizes pancreatic KATP channels (SUR1/Kir6.2) and cardiac KATP channels (SUR2A/Kir6.2). ZD0947 is potentially used to inhibit overactive bladder (OAB) .
|
-
- HY-126763
-
|
|
Phosphodiesterase (PDE)
Calcium Channel
|
Others
|
|
ATI22-107 is a dual-pharmacophore compound designed to simultaneously inhibit cardiac phosphodiesterase (PDE-III) and L-type calcium channels (LTCC), with activity that has specific effects on calcium cycling and contractility in cat ventricular myocytes and trabeculae.
|
-
- HY-15292
-
S107
1 Publications Verification
|
Calcium Channel
|
Cardiovascular Disease
|
|
S107 is an orally available, blood brain barrier-permeable compound, which stabilizes RyR2 channels by enhancing the binding of calstabin 2 to the mutant Ryr2-R2474S channel. S107 inhibits Ca 2+ leakage from the sarcoplasmic reticulum (SR) and prevents cardiac arrhythmias and raises the seizure threshold .
|
-
- HY-W010950
-
|
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
- HY-18600AS
-
|
NE-10064-dd8 dihydrochloride
|
Isotope-Labeled Compounds
Potassium Channel
|
Cardiovascular Disease
|
|
Azimilide-d8 (dihydrochloride) is the deuterium labeled Azimilide dihydrochloride. Azimilide Dihydrochloride (NE-10064 Dihydrochloride) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
|
-
- HY-B0632S
-
|
|
Isotope-Labeled Compounds
Calcium Channel
|
Cardiovascular Disease
|
|
Diltiazem-d6 is the deuterium labeled Diltiazem. Diltiazem is an orally active L-type Ca2+ channel blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .
|
-
- HY-121183
-
|
RP 52891
|
Potassium Channel
|
Cardiovascular Disease
|
|
Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions .
|
-
- HY-W010950A
-
|
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
- HY-19141
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
L-691121 exhibits antiarrhythmic efficacy through block of potassium channel and a followed prolonged cardiac potential. L-691121 exhibits embryotoxicity with fetal mortality at the dose of 0.8 mg/kg/day (p.o.). L-691121 is orally active .
|
-
- HY-126704
-
|
KC-8857
|
Potassium Channel
|
Cardiovascular Disease
|
|
Tedisamil (KC-8857) is an antiarrhythmic compound with important biological activities. Tedisamil exhibits a significant slowing effect on heart rate, which is achieved by inhibiting the transient outward potassium current (I(to)) in the atrium. Tedisamil inhibits multiple potassium currents, including IK, K(ATP), and PKA-activated chloride channels, thereby prolonging the cardiac action potential and QT interval, and increasing cardiac reentry. Tedisamil has antiarrhythmic effects on ventricular arrhythmias and atrial flutter in animal models .
|
-
- HY-B1440R
-
|
|
Calcium Channel
Monoamine Oxidase
|
Cardiovascular Disease
|
|
Ethaverine (hydrochloride) (Standard) is the analytical standard of Ethaverine (hydrochloride). This product is intended for research and analytical applications. Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease .
|
-
- HY-B0632S2
-
-
- HY-101128R
-
|
FR2054 (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Ethaverine (hydrochloride) (Standard) is the analytical standard of Ethaverine (hydrochloride). This product is intended for research and analytical applications. Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease .
|
-
- HY-17429S
-
|
R-818-d4
|
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide-d4 (acetate) is the deuterium labeled Flecainide acetate. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential .
|
-
- HY-116838
-
|
|
Bacterial
|
Infection
|
|
TAM-16 is a potent and orally active polyketide synthase 13 (Pks13) inhibitor with an IC50 value of 0.32 μM. TAM-16 has promising activity against Mycobacterium tuberculosis. TAM-16 inhibits hERG cardiac ion channel .
|
-
- HY-B0632R
-
|
|
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
Diltiazem (Standard) is the analytical standard of Diltiazem. This product is intended for research and analytical applications. Diltiazem is an orally active L-type Ca 2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .
|
-
- HY-P5319
-
|
|
Others
Calcium Channel
|
Others
|
|
MCaE12A is a high-affinity modulator of RyR2 and increases RyR2 sensitivity to cytoplasmic calcium concentrations promoting channel opening. MCaE12A acts as an important tool for RyR2 structure-to-function studies as well as for manipulating Ca2+ homeostasis and dynamic of cardiac cell .
|
-
- HY-17429R
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide (acetate) (Standard) is the analytical standard of Flecainide (acetate). This product is intended for research and analytical applications. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.
|
-
- HY-126401
-
|
IQB-875 free base
|
Calcium Channel
|
Cardiovascular Disease
|
|
Elgodipine (IQB-875 free base) is an orally active dihydropyridine calcium antagonist and an antianginal compound. Elgodipine inhibits both T- and L-type calcium channels (IC50: 32 and 2.3 nM). Elgodipine lowers systemic vascular resistance and improves systolic cardiac function .
|
-
- HY-W010950S
-
|
|
Potassium Channel
Sodium Channel
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
Flecainide-d3 is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
- HY-103059
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
SOICR-IN-1 (compound 32) is a store-overload induced calcium release (SOICR) inhibitor with an IC50 value of 14.6 μM. SOICR-IN-1 can be used for the research of cardiac arrhythmias .
|
-
- HY-B0162
-
|
|
HCN Channel
|
Cardiovascular Disease
Cancer
|
|
Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-B0632B
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
(2R,3R)-Diltiazem hydrochloride is an isomer of Diltiazem (HY-B0632) hydrochloride. Diltiazem is an orally active L-type Ca 2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .
|
-
- HY-W019726S1
-
|
BAY-b 4759-13C,d3
|
Isotope-Labeled Compounds
Drug Metabolite
|
Cancer
|
|
Dehydro Nifedipine-13C,d3 is a deuterated labeled Dehydro Nifedipine . Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies .
|
-
- HY-B0162A
-
|
|
HCN Channel
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-B0252
-
|
HCTZ
|
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-19765
-
|
|
TRP Channel
|
Cardiovascular Disease
|
|
GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research .
|
-
- HY-117055
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Ro 18-3981 is a dihydropyridine that inhibits cardiac Ca 2+ channels. Ro 18-3981 shows higher inhibitory activity when the cell membrane is in a depolarized state (Vh=-20 mV: IC50=2.3 nM; Vh=-50 mV: IC50=100 nM) .
|
-
- HY-19216
-
|
SKP 450
|
Potassium Channel
|
Cardiovascular Disease
|
|
KR-30450 (SKP 450) is a potent K +ATP opener, and a potassium channel activator. KR-30450 exerts more potent cardioprotective effects than Lemakalim (HY-14255). KR-30450 significantly improves reperfusion cardiac function. KR-30450 significantly attenuates reperfusion contracture and lactate dehydrogenase release .
|
-
- HY-W010950R
-
|
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
- HY-14290R
-
|
P-1134 (Standard)
|
Reference Standards
Potassium Channel
|
Cardiovascular Disease
|
|
Pinacidil (Standard) is the analytical standard of Pinacidil. This product is intended for research and analytical applications. Pinacidil is a potent activator of ATP-sensitive potassium channel. Pinacidil is an antihypertensive agent hyperpolarizes vascular smooth muscle by opening K + channels. Pinacidil enhances K +-efflux in smooth muscle. Pinacidil has vasorelaxant properties. Pinacidil is able to inhibit spontaneous tone and of reducing agonist induced contractions. Pinacidil can be studied in research area such as cardiovascular diseases .
|
-
- HY-B0162S
-
|
|
HCN Channel
|
Cardiovascular Disease
|
|
Ivabradine-d6 is the deuterium labeled Ivabradine . Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-135746
-
-
- HY-108591
-
|
R-L3
|
Potassium Channel
|
Cardiovascular Disease
|
|
L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
|
-
- HY-B0252S
-
|
HCTZ-d2
|
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-108998
-
|
|
Histone Methyltransferase
|
Cardiovascular Disease
|
|
Bisaramil hydrochloride is an antiarrhythmic compound with activity in inhibiting free radical generation. Bisaramil hydrochloride directly blocks sodium currents and exhibits enhanced sodium channel blocking ability. Bisaramil hydrochloride inhibits isoproterenol-induced slow calcium action potentials in cardiomyocytes. Bisaramil hydrochloride reduces heart rate and prolongs the PR, QRS, and QT intervals in the electrocardiogram, showing blocking effects on sodium and potassium channels. Bisaramil hydrochloride reduces cardiac conduction velocity, increases the threshold current for capture and atrial fibrillation, and prolongs the effective refractory period. Bisaramil hydrochloride reduces ventricular arrhythmias and eliminates mortality caused by ventricular fibrillation in ischemic rat hearts .
|
-
- HY-118148
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents .
|
-
- HY-B0252R
-
|
HCTZ (Standard)
|
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Hydrochlorothiazide (Standard) is the analytical standard of Hydrochlorothiazide. This product is intended for research and analytical applications. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-B0162AR
-
|
|
HCN Channel
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Ivabradine (hydrochloride) (Standard) is the analytical standard of Ivabradine (hydrochloride). This product is intended for research and analytical applications. Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-B0252S2
-
|
HCTZ-13C6
|
TGF-beta/Smad
Potassium Channel
|
Metabolic Disease
|
|
Hydrochlorothiazide- 13C6 is the 13C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-100607A
-
|
ONO1101 hydrochloride
|
Adrenergic Receptor
Calcium Channel
Potassium Channel
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury .
|
-
- HY-100607
-
|
ONO1101
|
Adrenergic Receptor
Calcium Channel
Potassium Channel
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury .
|
-
- HY-B1194
-
|
(±)-Tetramisole hydrochloride; DL-Tetramisole hydrochloride; R-829
|
Potassium Channel
Parasite
PKA
|
Infection
Cardiovascular Disease
|
|
Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
|
-
- HY-B1194A
-
|
|
Potassium Channel
Parasite
PKA
|
Infection
Cardiovascular Disease
|
|
Tetramisole is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
|
-
- HY-B0252S1
-
|
HCTZ-13C,d2
|
Isotope-Labeled Compounds
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Hydrochlorothiazid- 13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-103137R
-
|
|
Reference Standards
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Zacopride (hydrochloride) (Standard) is the analytical standard of Zacopride (hydrochloride). This product is intended for research and analytical applications. Zacopride hydrochloride is a highly potent 5-HT3 receptor antagonist with Kis of 0.38 and 373 nM for 5-HT3 and 5-HT4 receptor, respectively. Zacopride hydrochloride is also a moderate IK1 channel agonist. Zacopride hydrochloride exerts significant antiarrhythmic and cardiac protective effects .
|
-
- HY-N7491A
-
|
|
Calcium Channel
|
Cancer
|
|
ent-(+)-verticilide is a potent and selective inhibitor of cardiac ryanodine receptor (RyR2) calcium release channels with antiarrhythmic activity. ent-(+)-verticilide inhibits RyR2-mediated diastolic Ca 2+?leak and exhibits higher potency and a distinct mechanism of action compared with theDantrolene and Tetracaine.?ent-(+)-verticilide is a useful tool to investigate the therapeutic potential of targeting RyR2 hyperactivity in heart and brain pathologies .
|
-
- HY-106577
-
|
Cifenline; Ro 22-7796
|
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-144652
-
-
- HY-101390B
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Niguldipine free base is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine free base can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine free base exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine free base also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine free base on myocardial metabolism is not significant .
|
-
- HY-B1906
-
|
Agrept; Agrimycin; Streptomycin A
|
Antibiotic
Bacterial
|
Infection
Neurological Disease
|
|
Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
|
-
- HY-B0252S3
-
|
HCTZ-15N2,13C,d2
|
Potassium Channel
TGF-beta/Smad
Isotope-Labeled Compounds
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Hydrochlorothiazide- 15N2, 13C,d2 is 15N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-106761
-
|
|
Calcium Channel
|
Cardiovascular Disease
Others
|
|
Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs .
|
-
- HY-14290
-
|
P-1134
|
Potassium Channel
|
Cardiovascular Disease
|
|
Pinacidil (P-1134) is a potent activator of ATP-sensitive potassium channel. Pinacidil is an antihypertensive agent hyperpolarizes vascular smooth muscle by opening K + channels. Pinacidil enhances K +-efflux in smooth muscle. Pinacidil has vasorelaxant properties. Pinacidil is able to inhibit spontaneous tone and of reducing agonist induced contractions. Pinacidil can be studied in research area such as cardiovascular diseases .
|
-
- HY-B1194R
-
|
(±)-Tetramisole hydrochloride (Standard); DL-Tetramisole hydrochloride (Standard); R-829 (Standard)
|
Potassium Channel
Parasite
PKA
|
Infection
Cardiovascular Disease
|
|
Tetramisole hydrochloride (Standard) is the analytical standard of Tetramisole (hydrochloride). This product is intended for research and analytical applications. Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
|
-
- HY-100607AR
-
|
ONO1101 hydrochloride (Standard)
|
Reference Standards
Adrenergic Receptor
Calcium Channel
Potassium Channel
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Landiolol (ONO1101) hydrochloride (Standard) is the analytical standard of Landiolol hydrochloride (HY-100607A). This product is intended for research and analytical applications. Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury .
|
-
- HY-106577R
-
|
Cifenline (Standard); Ro 22-7796 (Standard)
|
Reference Standards
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-106577S
-
|
Cifenline-d4; Ro 22-7796-d4
|
Isotope-Labeled Compounds
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline-d4 (Cifenline-d4) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-B1906R
-
|
|
Antibiotic
Bacterial
|
Infection
Neurological Disease
|
|
Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
|
-
- HY-107813R
-
|
BAY 41-6551 sulfate (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
|
-
- HY-106577S1
-
|
Cifenline-d5; Ro 22-7796-d5
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline-d5 (Cifenline-d5) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-B0653
-
|
(S)-(-)-Bupivacaine
|
Sodium Channel
Ferroptosis
|
Neurological Disease
Cancer
|
|
Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
|
-
- HY-B0653A
-
|
(S)-(-)-Bupivacaine monohydrochloride
|
Sodium Channel
Ferroptosis
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
|
-
- HY-B0407A
-
|
|
Dopamine Receptor
Autophagy
Cytochrome P450
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .
|
-
- HY-12708
-
Chlorpromazine
Maximum Cited Publications
69 Publications Verification
|
Dopamine Receptor
Cytochrome P450
Autophagy
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Chlorpromazine is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine also can inhibit clathrin-mediated endocytosis .
|
-
- HY-A0148
-
|
SKF-102886 free base; WR-171669
|
Parasite
Potassium Channel
|
Infection
Cancer
|
|
Halofantrine (SKF-102886 free base) is a highly lipophilic antimalarial active against Chloroquine-resistant strains of Plasmodium falciparum . Halofantrine blocks HERG potassium channels .
|
-
- HY-B0407AR
-
|
|
Reference Standards
Dopamine Receptor
Autophagy
Cytochrome P450
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .
|
-
- HY-W041470R
-
|
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .
|
-
- HY-10672
-
|
|
Urotensin Receptor
Cytochrome P450
Sodium Channel
Opioid Receptor
|
Cardiovascular Disease
|
|
Urotensin-II receptor antagonist-1 (compound 1) is a low oral bioavailability (F=0-3%, rat) selective human Urotensin II receptor antagonist, Ki=16 nM (test on HEK293 cells expressing recombinant human UT receptor). Urotensin-II receptor antagonist-1 inhibits cytochrome P450 (IC50=0.75 μM, CYP2D6; 1.4 μM, CYP3A4), inhibits κ-opioid receptor (EC50=3.2 μM), targets cardiac sodium channels (Ki=2.5 μM) .
|
-
- HY-B0653AS
-
|
(S)-(–)-Bupivacaie-d9(hydrochloride)
|
Isotope-Labeled Compounds
Ferroptosis
Sodium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Levobupivacaine-d9 ((S)-(–)-Bupivacaie-d9) hydrochloride is deuterium labeled Levobupivacaine hydrochloride (HY-B0653A). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
|
-
-
-
HY-L118
-
|
|
161 compounds
|
|
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.
MCE offers a unique collection of 161 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.
|
| Cat. No. |
Product Name |
Type |
-
- HY-107754
-
|
|
Biochemical Assay Reagents
|
|
Cesium chloride is a blocker of potassium channel. Cesium chloride prevents the decrease of Na + transport produced by Alloxan . Cesium chloride has induced cardiac arrhythmias, including torsade de pointes in animal models .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4898A
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
Anthopleurin-A TFA is a soidum channel toxin. Anthopleurin-A TFA is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A TFA can be isolated from the sea anemone .
|
-
- HY-P1219
-
|
β-TRTX-Cj1α
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC50 of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype .
|
-
- HY-P4898
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
Anthopleurin-A is a soidum channel toxin. Anthopleurin-A is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A can be isolated from the sea anemone .
|
-
- HY-P5772
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-II, a 32 amino acid residues including two acidic and two basic residues, is a neurotoxin. Jingzhaotoxin-II inhibits voltage-gated sodium channels (VGSC) that significantly slows rapid inactivation of TTX-resistant (TTX-R) VGSC on cardiac myocytes with the IC50 of 0.26 μM .
|
-
- HY-P5319
-
|
|
Peptides
Calcium Channel
|
Others
|
|
MCaE12A is a high-affinity modulator of RyR2 and increases RyR2 sensitivity to cytoplasmic calcium concentrations promoting channel opening. MCaE12A acts as an important tool for RyR2 structure-to-function studies as well as for manipulating Ca2+ homeostasis and dynamic of cardiac cell .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B1906
-
|
Agrept; Agrimycin; Streptomycin A
|
Microorganisms
Source classification
|
Antibiotic
Bacterial
|
|
Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
|
-
-
- HY-B1906R
-
|
|
Microorganisms
Source classification
|
Antibiotic
Bacterial
|
|
Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .
|
-
-
- HY-W041470R
-
|
|
Structural Classification
Ketones, Aldehydes, Acids
Source classification
Endogenous metabolite
|
Reference Standards
Endogenous Metabolite
|
|
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-12515AS
-
|
|
|
Nicardipine-d3 hydrochloride (YC-93 D3) is the deuterium labeled Nicardipine hydrochloride. Nicardipine hydrochloride is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-B0341S
-
|
|
|
Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-17429S
-
|
|
|
Flecainide-d4 (acetate) is the deuterium labeled Flecainide acetate. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential .
|
-
-
- HY-B0284S1
-
|
|
|
Nifedipine-d4 is the deuterium labeled Nifedipine. Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
|
-
-
- HY-12515AS2
-
|
|
|
Nicardipine-d4 hydrochloride is deuterated labeled Nicardipine hydrochloride (HY-12515A). Nicardipine hydrochloride (YC-93) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .
|
-
-
- HY-B0284S2
-
|
|
|
Nifedipine-13C8 is a deuterated labeled Nifedipine . Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
|
-
-
- HY-18600AS
-
|
|
|
Azimilide-d8 (dihydrochloride) is the deuterium labeled Azimilide dihydrochloride. Azimilide Dihydrochloride (NE-10064 Dihydrochloride) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
|
-
-
- HY-B0632S
-
|
|
|
Diltiazem-d6 is the deuterium labeled Diltiazem. Diltiazem is an orally active L-type Ca2+ channel blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .
|
-
-
- HY-B0632S2
-
|
|
|
Diltiazem-d4 is deuterium labeled Diltiazem. Diltiazem is an orally active L-type Ca 2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .
|
-
-
- HY-W010950S
-
|
|
|
Flecainide-d3 is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
-
- HY-W019726S1
-
|
|
|
Dehydro Nifedipine-13C,d3 is a deuterated labeled Dehydro Nifedipine . Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies .
|
-
-
- HY-B0162S
-
|
|
|
Ivabradine-d6 is the deuterium labeled Ivabradine . Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
-
- HY-B0252S
-
|
|
|
Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
-
- HY-B0252S2
-
|
|
|
Hydrochlorothiazide- 13C6 is the 13C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
-
- HY-B0252S1
-
|
|
|
Hydrochlorothiazid- 13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
-
- HY-B0252S3
-
|
|
|
Hydrochlorothiazide- 15N2, 13C,d2 is 15N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
-
- HY-106577S
-
|
|
|
Cibenzoline-d4 (Cifenline-d4) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
-
- HY-106577S1
-
|
|
|
Cibenzoline-d5 (Cifenline-d5) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
-
- HY-B0653AS
-
|
|
|
Levobupivacaine-d9 ((S)-(–)-Bupivacaie-d9) hydrochloride is deuterium labeled Levobupivacaine hydrochloride (HY-B0653A). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
